Screener
Ligand Pharmaceuticals LGND Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current contingent liabilities | 210 | 287 |
| Current operating lease liabilities | 1,082 | 1,095 |
| Other current liabilities | 955 | 135 |
| Total current liabilities | 46,736 | 37,447 |
| Long-term contingent liabilities | 2,382 | 2,934 |
| Long-term operating lease liabilities | 3,777 | 4,204 |
| Convertible senior notes, net | 1,126,594 | 446,192 |
| Deferred income taxes, net | 21,654 | 36,019 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's total current liabilities?
- Ligand Pharmaceuticals (LGND) reported total current liabilities of $46.74M in Q2 2026.
- How has Ligand Pharmaceuticals's total current liabilities changed year-over-year?
- Ligand Pharmaceuticals's total current liabilities decreased by 27.8% year-over-year, from $64.73M to $46.74M.
- What is the long-term trend for Ligand Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's total current liabilities has grown at a -17.9% compound annual growth rate (CAGR), from $100.11M to $37.45M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Ligand Pharmaceuticals's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude